Spironolactone 25mg tabs 20 pcs ozone

Description

Composition
Active substance:
1 tablet contains: 25.0 mg cpironolakton.
Product form:
Tablets 25 mg. 10, 20 tablets in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50 or 100 tablets in banks of PET for drugs sealed with lids screw-with the control of the first opening or the system “push-turn” of polypropylene or polyethylene, or cans made of polypropylene for drugs sealed with lids tautened a first opening control of the high-pressure polyethylene. One jar or 1, 2, 3, 4 or 5 contour cell packages together with instructions for use placed in a cardboard box (pack).
Contraindications
– Increased sensitivity to spironolactone and any of the components. – Addison’s disease; – hyperkalemia; – hyponatremia; – severe renal impairment (creatinine clearance less than 10 mL / min); – anuria; – lack of lactose intolerance lactase, a syndrome of glucose-galactose malabsorption; – pregnancy; – lactation (breast feeding); – Children under 3 years of age (a solid dosage form); – simultaneous application of eplerenone and other potassium-sparing diuretics, potassium preparations (risk of hyperkalemia).
Dosage
25 mg
Indications
– Essential hypertension (as part of combination therapy); – Edematous syndrome in chronic heart failure (it can be applied in monotherapy or in combination therapy); – a state in which can be detected secondary hyperaldosteronism, including cirrhosis of the liver accompanied by ascites and / or edema, nephrotic syndrome, and other conditions accompanied by edema; – hypokalaemia / hypomagnesaemia (as an auxiliary means for preventing it during treatment with diuretics inability to use other ways of correction of potassium content); – primary hyperaldosteronism (Conn syndrome) – short for preoperative treatment; – for the diagnosis of primary hyperaldosteronism; – severe chronic heart failure (III-IV functional class NYHA classification) with standard therapy.
pharmachologic effect
Pharmacological group:
Potassium-sparing diuretic agent.
Pharmacological properties:
Potassium-sparing diuretic action is due to antagonism of aldosterone (mineralokortikosteroidny adrenocortical hormone). Aldosterone promotes the reabsorption of sodium ions in the renal tubules and increases the excretion of potassium ions. Spironolactone – a competitive antagonist of aldosterone for influencing the distal nephron (competes for binding sites on the cytoplasmic protein receptors, reduces the synthesis permeases in aldosteronzavisimom portion of the collecting ducts and distal tubules), increases the excretion of sodium, chloride and water and reduce the excretion of potassium ion and urea, It reduces the acidity of urine. Increased diuresis causes the antihypertensive effect, which unstable. The diuretic effect is seen on the 2-5 day of treatment.
Conditions of supply of pharmacies
Prescription.
Dosing and Administration
Inside. Along with the meal. In essential hypertension: A daily dose for adults is usually 50-100 mg once daily and may be increased to 200 mg, the dose should be increased gradually, one every 2 weeks. To achieve an adequate response to therapy, the drug should be taken at least 2 weeks. If necessary, a dose correction. Idiopathic hyperaldosteronism: 100-400 mg / day. When expressed hyperaldosteronism and hypokalemia: The daily dose is 300 mg / day (maximum 400 mg) for 2-3 hours, while improving the dose was gradually reduced to 25 mg / day. When hypokalemia and / or hypomagnesemia caused diuretic therapy: assigning drug dose of 25-100 mg / day. once or in several stages. The maximum daily dose of 400 mg when potassium formulations for ingestion or other methods compensate the deficit ineffective.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist